Department of Hospital Pharmacy, Erasmus MC.
Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC.
Ther Drug Monit. 2021 Jun 1;43(3):351-357. doi: 10.1097/FTD.0000000000000834.
Dried blood spots (DBSs) have gained recent popularity as a sampling method for therapeutic drug monitoring. For patients, DBS sampling has several advantages over venous blood sampling. However, technical issues primarily influenced by hematocrit levels, interfere with the implementation of this method in daily clinical practice. The results of concentration measurements of drugs that are influenced by hematocrit should be corrected for hematocrit levels. In this article, we developed a fast, nondestructive, near-infrared (NIR)-based method for measuring the hematocrit in DBSs.
Using a partial least squares algorithm, an NIR-based quantification method was developed for measuring hematocrit levels of 0.19-0.49 L/L. Residual venous blood of 522 patients was used to build this partial least squares model. The validity of the method was evaluated using 40 patient samples. DBSs were created by adding a small amount (50 µL) of blood on a Whatman filter paper and drying for 24 hours in a desiccator cabinet. The robustness was evaluated by measuring 24 additional samples with a high hemolysis, icterus, and lipemia (HIL) index. The hematocrit values obtained using a Sysmex XN hemocytometry analyzer were used as reference.
The difference between hematocrit measurements obtained with NIR spectroscopy and a hemocytometry analyzer was <15% for the 40 samples. The accuracy (≤9%) and precision (≤7%) for all the quality control samples were within the acceptance criteria of <15%. The intraassay and interassay coefficient of variability was ≤3% and ≤6%, respectively, for the different quality control levels. There were no deviations in the measurements for the samples with high HIL indices. The stability of hematocrit in DBS was up to 14 days for all levels.
We developed and validated a hematocrit model using NIR spectroscopy. This nondestructive, accurate, and reproducible method has a short analysis time (51 seconds), and can be used to analyze DBS samples stored for up to 2 weeks in a desiccator cabinet.
干血斑 (DBS) 作为治疗药物监测的采样方法最近受到了关注。对于患者而言,DBS 采样相对于静脉采血具有多项优势。然而,主要受红细胞压积水平影响的技术问题,干扰了该方法在日常临床实践中的实施。应校正红细胞压积影响的药物浓度测量结果,以校正红细胞压积水平。在本文中,我们开发了一种快速、无损、近红外 (NIR) 方法,用于测量 DBS 中的红细胞压积。
使用偏最小二乘算法,开发了一种基于 NIR 的定量方法,用于测量 0.19-0.49 L/L 的红细胞压积水平。使用 522 名患者的剩余静脉血来建立该偏最小二乘模型。使用 40 名患者样本评估该方法的有效性。通过在 Whatman 滤纸上添加少量 (50 µL) 血液并在干燥柜中干燥 24 小时来创建 DBS。通过测量 24 个具有高溶血、黄疸和脂血 (HIL) 指数的额外样本来评估稳健性。使用 Sysmex XN 血细胞计数分析仪获得的红细胞压积值用作参考。
在 40 个样本中,NIR 光谱法与血细胞计数分析仪法测量的红细胞压积值差异<15%。对于所有质控样本,准确度 (≤9%) 和精密度 (≤7%) 均在接受标准内(<15%)。不同质控水平的日内和日间变异系数分别为≤3%和≤6%。HIL 指数较高的样本测量值无偏差。对于所有水平,DBS 中的红细胞压积在 14 天内保持稳定。
我们使用 NIR 光谱法开发并验证了红细胞压积模型。这种无损、准确且可重复的方法具有较短的分析时间(51 秒),可用于分析在干燥柜中储存长达 2 周的 DBS 样本。